Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis

Fig. 5

(Zn-Adenine)@Ab@lncRNA LEF1-AS1 inhibited RASFs growth via the miR-30-5p/PIK3R2 pathway. A Viability of RASFs treated with the NPs for 0, 24, or 48 h. B–D Number of cells, colony formation assay, and H&E staining in the indicated groups. E Apoptosis rates in the cells treated as indicated. F PIK3R2 mRNA levels in the indicated groups. G–H Immunoblot showing PIK3R2, PI3K, p-PI3K, AKT, and p-AKT protein levels. Experiments were repeated thrice (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us